Current Clinical Applications of In Vivo Gene Therapy with AAVs.
Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, Boye SL, Boye SE, George LA, Salabarria S, Corti M, Byrne BJ, Tremblay JP.
Mol Ther. 2021 Feb 3;29(2):464-488. doi: 10.1016/j.ymthe.2020.12.007. Epub 2020 Dec 10.
Revolution in evolution.
Honavar SG.
Indian J Ophthalmol. 2018 Dec;66(12):1667. doi: 10.4103/ijo.IJO_1894_18.
Snowflake degeneration in hereditary vitreoretinal degeneration.
Hirose T, Lee KY, Schepens CL.
Am J Ophthalmol. 1974 Feb;77(2):143-53. doi: 10.1016/0002-9394(74)90665-5.
Hereditary snowflake vitreoretinal degeneration.
Gheiler M, Pollack A, Uchenik D, Godel V, Oliver M.
Birth Defects Orig Artic Ser. 1982;18(6):577-80.
Goldmann-Favre vitreoretinal degeneration.
Batioğlu F.
Eur J Ophthalmol. 2003 Apr;13(3):307-10. doi: 10.1177/112067210301300311.
Hereditary vitreoretinal degeneration and night blindness.
Feiler-Ofry V, Adam A, Regenbogen L, Godel V, Stein R.
Am J Ophthalmol. 1969 Apr;67(4):553-8. doi: 10.1016/0002-9394(69)94263-9.
Optical Coherence Tomography.
Enaholo ES, Musa MJ, Zeppieri M.
2024 Oct 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
Wagner's hereditary vitreoretinal degeneration.
Manning LM.
Aust J Ophthalmol. 1980 Feb;8(1):29-33. doi: 10.1111/j.1442-9071.1980.tb00885.x.
Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: a phase 1/2, multicentre, open-label, unilateral dose escalation study.
Yang P, Pardon LP, Ho AC, Lauer AK, Yoon D, Boye SE, Boye SL, Roman AJ, Wu V, Garafalo AV, Sumaroka A, Swider M, Viarbitskaya I, Aleman TS, Pennesi ME, Kay CN, Fujita KP, Cideciyan AV.
Lancet. 2024 Sep 7;404(10456):962-970. doi: 10.1016/S0140-6736(24)01447-8.
Hereditary vitreoretinal diseases.
Neetens A.
Bull Soc Belge Ophtalmol. 1987;223 Pt 1:241-72. doi: 10.1007/978-1-4757-1901-7_16.
